trending Market Intelligence /marketintelligence/en/news-insights/trending/n17qifydqfyn4ec_rtpk9g2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Ablynx's autoimmune disease drug misses main goal in phase 2 study

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021


Ablynx's autoimmune disease drug misses main goal in phase 2 study

Ablynx NV said its drug vobarilizumab failed to meet the main goal in a phase 2 study for treating the disease known as lupus.

In the trial, dubbed Steady, patients failed to respond to various doses of the drug after 24 weeks. The trial enrolled 312 patients suffering from moderate to severe active seropositive systemic lupus erythematosus.

Lupus is an autoimmune disease in which the immune system mistakenly attacks healthy tissue in different parts of the body, resulting in pain and swelling.

Sanofi is acquiring Ablynx in a €3.9 billion deal, looking to bulk up on therapies for rare diseases.